Doxylamine succinate - Generic Drug Details

What are the generic drug sources for doxylamine succinate and what is the scope of patent protection?

Doxylamine succinate is the generic ingredient in eight branded drugs marketed by Pfizer, Sanofi Aventis Us, Par Pharm, Copley Pharm, LNK, Perrigo, Quantum Pharmics, Chattem, Duchesnay, Actavis Labs Fl Inc, Bionpharma, Mylan Pharms Inc, and Ph Health, and is included in sixteen NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for doxylamine succinate. Thirty-two suppliers are listed for this compound.

Summary for doxylamine succinate

US Patents:	4
Tradenames:	8
Applicants:	13
NDAs:	16
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	32
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	7
Patent Applications:	2,414
What excipients (inactive ingredients) are in doxylamine succinate?	doxylamine succinate excipients list
DailyMed Link:	doxylamine succinate at DailyMed

Recent Clinical Trials for doxylamine succinate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nawaz Sharif Medical College	NA
University of Gujrat	NA
Jiangxi Maternal and Child Health Hospital	Phase 3

See all doxylamine succinate clinical trials

Pharmacology for doxylamine succinate

Drug Class	Antihistamine
Mechanism of Action	Histamine Receptor Antagonists

Medical Subject Heading (MeSH) Categories for doxylamine succinate

Antiemetics

Histamine H1 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for doxylamine succinate

R06AA	Aminoalkyl ethers
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

US Patents and Regulatory Information for doxylamine succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnk	DOXYLAMINE SUCCINATE	doxylamine succinate	TABLET;ORAL	040564-001	Aug 27, 2004		OTC	No	No
Sanofi Aventis Us	BENDECTIN	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	010598-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	DECAPRYN	doxylamine succinate	TABLET;ORAL	006412-015	Approved Prior to Jan 1, 1982		DISCN	No	No
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	9,089,489		Y

Market Dynamics and Financial Trajectory for Doxylamine Succinate

Last updated: July 27, 2025

---

Introduction

Doxylamine succinate, a first-generation antihistamine with sedative properties, has maintained relevance primarily as a component in over-the-counter sleep aids and relief formulations for allergies. While not a groundbreaking pharmaceutical innovation, its longstanding presence in the market renders it an archetype of stability amid fluctuating regulatory and consumer trends. This analysis explores the market dynamics influencing doxylamine succinate, alongside its financial trajectory, driven by evolving healthcare needs, regulatory frameworks, and competitive acts within the broader antihistamine and sedative segments.

---

Market Overview and Demand Drivers

Existing Therapeutic Use and Consumer Preference

Doxylamine succinate is predominantly used for short-term sleep management and allergy symptoms. Its over-the-counter (OTC) availability in formulations like Unisom SleepTabs underpins a consistent base of demand. The preference for OTC remedies over prescribed medication confers advantages: ease of access, lower costs, and fewer regulatory hurdles, fostering steady sales trajectories.

Demographic and Consumer Trends

An aging population globally, coupled with increased prevalence of sleep disorders, sustains demand. The American Psychological Association reports that approximately 50-70 million adults in the U.S. suffer from sleep disturbances, underpinning a resilient OTC sleep aid market. Simultaneously, societal stressors amidst a post-pandemic environment heighten the reliance on OTC sedatives like doxylamine.

Emerging Competition and Formulation Trends

Despite its stability, doxylamine succinate faces competition from newer sedatives, non-benzodiazepine hypnotics, and alternative therapies such as melatonin. There is also a rising inclination toward "clean-label" products with natural ingredients, challenging synthetic antihistamines’ market share. However, due to its proven efficacy and familiarity, doxylamine’s market niche remains substantial.

---

Regulatory Environment and Impact

Regulatory Considerations

Doxylamine succinate’s OTC status in markets such as the U.S. depends on compliance with FDA regulations. Post-approval, ongoing monitoring for safety concerns—such as adverse anticholinergic effects—is essential. Regulatory bodies have historically maintained its status, with occasional warnings about potential side effects, but no significant restrictions have emerged recently.

Patent and Exclusivity Landscape

As a generic compound, doxylamine succinate lacks recent patent protections, contributing to a highly competitive pricing environment. Patent expirations of formulations have facilitated widespread manufacturing, diminishing potential for premium pricing but ensuring a consistent supply.

---

Competitive Landscape

Market Players and Product Diversification

Firms such as Johnson & Johnson (via Unisom) dominate the OTC sleep aid market, offering various formulations with doxylamine succinate. Generic manufacturers also produce cost-competitive equivalents, leading to price erosion and thin margins but preserving market volume.

Innovative Strategies

Some players incorporate doxylamine in combination therapies, such as in products targeting multiple sleep or allergy symptoms, facilitating incremental revenue streams. Co-branding with wellness brands or marketing targeted at specific demographics (e.g., seniors) further sustains sales.

---

Financial Trajectory and Revenue Outlook

Revenue Stability

The consistent demand driven by OTC sales ensures stable revenue streams for branded and generic manufacturers. The U.S. OTC sleep aid market was valued at approximately $400 million in 2022, with doxylamine-based products representing a significant portion (per industry reports [1]).

Pricing Dynamics

The commoditization of doxylamine formulations has introduced downward pressure on prices. Margins are tight, but high volume sales compensate for reduced per-unit margins. Price sensitivity suggests that aggressive competition and emerging natural alternatives could further impact profitability.

Market Growth Potential

Forecasts indicate modest growth post-pandemic due to increased sleep disorder prevalence, aging populations, and consumer willingness to invest in OTC health solutions. However, the growth rate remains limited (~3-5% annually) due to substitutes and consumer preferences shifting towards natural sleep aids.

Potential for Market Expansion

Regulatory flexibility around formulations may facilitate new delivery formats—such as gummies or lozenges—potentially expanding consumption. Additionally, increased awareness of sleep health underscores potential for expanded indications, though regulatory approval pathways remain complex.

---

Market Challenges and Opportunities

Challenges

• Safety Concerns: Anticholinergic side effects pose risk for vulnerable populations, potentially leading to regulatory scrutiny or formulation restrictions.
• Competition from Natural Alternatives: The rising popularity of melatonin, valerian root, and other herbal remedies limits growth for synthetic antihistamines.
• Pricing Pressures: The proliferation of generics drives commoditization, squeezing profit margins.

Opportunities

• Product Innovation: Developing extended-release formulations or combination therapies can differentiate offerings.
• Market Expansion: Targeting emerging markets with large aging populations offers new revenue streams.
• Regulatory Pathways: Advances in regulatory science could facilitate approval for new indications, expanding market reach.

---

Conclusion

Doxylamine succinate continues to occupy a stable niche within the OTC sleep aid and allergy relief markets. Its market dynamics are predominantly shaped by demographic shifts, consumer preferences, and regulatory stability, fostering modest but steady financial growth. Nevertheless, increasing competition from natural products and concerns over safety profiles suggest future challenges in maintaining profitability levels. Strategic focus on product innovation, market expansion, and regulatory engagement will be crucial to sustain its financial trajectory.

---

Key Takeaways

• Stable Demand: Doxylamine succinate’s familiarity and OTC status underpin consistent consumer demand, especially in aging populations.
• Pricing Pressures: Market saturation and high generic competition suppress margins, emphasizing volume-driven revenue strategies.
• Regulatory Landscape: Relatively stable regulatory status allows continued market access; however, safety concerns could impose future constraints.
• Competition and Alternatives: Natural sleep aids present formidable substitutes, necessitating innovation and differentiation.
• Growth Opportunities: Emerging markets and new formulations offer potential avenues for expansion, provided regulatory and safety hurdles are navigated effectively.

---

FAQs

1. What are the main applications of doxylamine succinate?
Primarily used as an OTC sleep aid (e.g., Unisom) and allergy symptom reliever, leveraging its sedative and antihistamine properties.

2. How does the patent status influence the market for doxylamine succinate?
As a generic compound lacking recent patents, the market is highly competitive with low-cost manufacturers, limiting pricing power but ensuring widespread availability.

3. What regulatory challenges could impact doxylamine succinate’s market?
While currently stable, potential safety concerns about anticholinergic effects could lead to stricter regulations or formulation restrictions, impacting sales.

4. Which emerging trends threaten the market position of doxylamine-based products?
Preference for natural sleep aids like melatonin and herbal remedies pose a significant challenge, alongside consumer safety concerns regarding synthetic antihistamines.

5. What strategies could enhance the financial trajectory of doxylamine succinate?
Innovating formulations, expanding into emerging markets, and targeting niche demographics or indications can facilitate growth despite market pressures.

---

References:

[1] IBISWorld Industry Report, OTC Sleep Aid Market, 2022.